Privia Health Group (PRVA)
(Delayed Data from NSDQ)
$18.17 USD
-0.63 (-3.35%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $18.16 -0.01 (-0.06%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.17 USD
-0.63 (-3.35%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $18.16 -0.01 (-0.06%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
Zacks News
Privia Health (PRVA) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health (PRVA) Misses Q4 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OMCL vs. PRVA: Which Stock Is the Better Value Option?
Compared to Estimates, Privia Health (PRVA) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) Q3 Earnings Miss Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -16.67% and 1.59%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
GEHC or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GEHC vs. PRVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
GEHC vs. PRVA: Which Stock Is the Better Value Option?
Privia Health (PRVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 100% and 2.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Signify (SGFY): Can Its 5.8% Jump Turn into More Strength?
by Zacks Equity Research
Signify (SGFY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Options Traders Betting on a Big Move in Privia Health Group (PRVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Privia Health Group (PRVA) stock based on the movements in the options market lately.
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -400% and 7.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 8.11% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Privia Health (PRVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Change Healthcare (CHNG) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Change Healthcare (CHNG) delivered earnings and revenue surprises of -2.56% and 0.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Privia Health (PRVA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.